Lonza Group expands ADC capacity in Visp as demand for complex biologics grows

By Thomas Clarke, Operations & Strategy desk. Reviewed on June 30, 2026 at 2:55 p.m. ET.

Lonza Group AG (CH0013841017) has announced a fresh expansion of its highly potent active pharmaceutical ingredient capacity in Visp, Switzerland, targeting the fast-growing antibody-drug conjugate market according to a corporate release published on June 30, 2026. The move adds new payload-linker manufacturing capabilities designed to support clinical and commercial programs for complex oncology therapies.

New HPAPI investment in Visp

In a corporate statement carried by EQS News, Lonza said it will enhance its drug-linker center of excellence and expand payload-linker manufacturing capacity at its large Visp campus in Switzerland. The investment will add commercial-scale capabilities for manufacturing highly complex and highly potent ADC payload-linkers and related HPAPI, consolidating a key part of the oncology supply chain at a single integrated site.

The company plans to add new production and purification lines within an existing GMP facility at Visp, alongside dedicated analytical and process development laboratories, according to the same release. The new capacity is expected to be operational in 2028 and will support both clinical and commercial programs, allowing biopharma customers to bring innovative ADC therapies to market more quickly and at larger scale.

Strategic push in antibody-drug conjugates

The Visp expansion is designed to reinforce Lonza Group AG's position as a fully integrated contract development and manufacturing partner in the ADC segment, which relies on specialized payload-linker technologies to attach cytotoxic agents to antibodies. In its June 30 communication, the company highlighted that demand for ADC-related services is rising as more oncology pipelines include targeted conjugate therapies and as late-stage programs move toward commercialization.

An article on the Swiss finance portal finanzen.ch notes that the expansion at Visp focuses on payload-linkers, a central component of ADCs, and will be set up within an existing GMP production facility. The report also underscores that Lonza did not disclose the size of the investment but indicated that the new infrastructure is designed with flexibility, allowing for further scaling of payload-linker production if customer demand increases.

Contract development and ADC services

Lonza Group AG describes itself as a leading global contract development and manufacturing organization across biologics, small molecules and cell and gene therapies, with the ADC business forming part of its broader biologics offering. The Visp site already houses a range of HPAPI and biologics production capabilities, and the new payload-linker capacity is set to deepen that specialization so that customers can handle conjugation projects through a single CDMO partner rather than splitting work between multiple vendors.

Coverage of the Visp plan on FinanzNachrichten reproduces the corporate announcement and emphasizes that the additional capacity should support both clinical-stage and commercial-stage ADC programs at the same site. According to this report, Lonza expects the facility to improve time to market for ADC therapies by combining HPAPI production, payload-linker synthesis and analytical support under one roof in Visp.

Lonza stock and trading context

On the equity side, Lonza Group AG is listed on the SIX Swiss Exchange, where its shares trade in Swiss francs under ISIN CH0013841017. Market data compiled by finanzen.ch show a Swiss Exchange price of around CHF 546.00 in intraday trading on June 30, 2026, with an intraday range between CHF 539.80 and CHF 546.40 and trading volume above 27,000 shares at the quoted time.

The same price overview indicates that Lonza Group AG also has an over-the-counter ADR in the United States under the ticker LZAGY, providing a US-dollar entry point for investors who prefer not to access the Swiss market directly. According to a recent report on Zacks, the ADR was quoted at $66.90 as of late June 2026, and the research firm highlighted both a constructive technical pattern and upward revisions in earnings estimates in its commentary.

ADC payload-linkers as a growth driver

In the ADC value chain, payload-linkers are critical components that determine how a cytotoxic drug is attached to an antibody and how it is released at the tumor site, making reliable manufacturing of these highly potent molecules strategically important. Lonza's plan for additional payload-linker capacity in Visp, as outlined in its June 30 release, responds to rising demand from biopharma developers that are bringing multiple ADC assets into later-stage development and toward commercialization.

The EQS-distributed statement underscores that the new facility is intended to handle highly complex HPAPI and payload-linker chemistries at commercial scale and is integrated with Lonza's existing analytical and process development capabilities at Visp. By situating the expansion within an existing GMP environment, the company can leverage established quality systems and infrastructure while tailoring new equipment and labs around the specific needs of ADC payload-linker production.

Representative ADC-related service offering

Within Lonza Group AG's broader biologics portfolio, ADC development and manufacturing services stand out as a representative growth area, combining biologics expertise with small-molecule HPAPI capabilities. The Visp payload-linker center of excellence, which is now being expanded, offers support from early process development through to commercial-scale manufacturing of highly potent payload-linker molecules, including route development, scale-up, and analytical characterization.

By offering integrated services that cover the production of both the antibody and the payload-linker components, Lonza aims to reduce technical and logistical complexity for biopharma clients working on ADC programs. This integrated model can be particularly valuable for smaller biotech companies that may not have in-house capacity to manage highly potent chemistry or to coordinate multiple CDMOs across the ADC supply chain.

Lonza Group AG stock snapshot

Based on the intraday pricing information reported by finanzen.ch for the Swiss listing, Lonza Group AG shares traded at approximately CHF 546.00 on the SIX Swiss Exchange as of June 30, 2026, with the quote timestamp shortly after 2:00 p.m. local time in Switzerland. For US-based investors, the Lonza Group ADR LZAGY referenced by Zacks most recently closed at $66.90 on June 29, 2026, underscoring that liquidity is available both in Zurich-listed shares and in an over-the-counter US instrument.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.